Merck Ups R&D Spend Amid Avelumab Anticipation
This article was originally published in Scrip
Merck of Germany's R&D spend in immuno-oncology will be €150–200m higher in 2016 than in 2015, it said at its Capital Market Day (Dec. 10). Much of this will be allocated to the antibody avelumab, which Merck is co-developing with Pfizer, as well as to projects in early stages of clinical development. In total, Merck is planning additional investments of around €250m in its pharmaceutical pipeline.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.